• Simon Exell, Elisabetta Verdun, and Reinoud Driebergen.
• Merck Serono S.A.-Geneva*, 9 chemin des Mines, 1202 Geneva, Switzerland. simon.exell@merckserono.net
• Expert Rev Med Devices. 2011 Sep 1; 8 (5): 543-53.

AbstractDisease-modifying drugs (DMDs) can provide important benefits for patients with multiple sclerosis (MS), but nonadherence to treatment is associated with an increased risk of relapse. All first-line DMDs used in MS require regular injection, but injection-related problems are common barriers to treatment adherence. Autoinjectors that allow automatic injection at the press of a button have increased the ease and convenience of injection, compared with manual injection. A new electronic autoinjector has recently been introduced for the administration of subcutaneous IFN-β-1a. This device is the first electronic autoinjector for use with any MS therapy, and includes several innovative features that may be advantageous to patients. One of these features is an accurate electronic dosing log, which can be viewed by the patient and the healthcare provider. This article discusses this new electronic device in the context of other autoinjectors currently used to self-inject first-line DMDs in MS.

24 keywords...

hide…